Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Status:
Active, not recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
The study will be conducted in three parts. Part 1 is a dose escalation phase to determine
the maximum tolerated dose (MTD) of INCB040093, a PI3Kδ inhibitor, or a tolerated,
pharmacologically active dose; Part 2 will evaluate the combination of INCB040093 and
itacitinib (INCB039110), a JAK1 inhibitor, to determine the MTD of the combination or a
tolerated dose that produces substantial pharmacologic inhibition of both targets; Part 3
will further evaluate the chosen doses of INCB040093 alone and in combination with itacitinib
(INCB039110) in subjects with relapsed/refractory B-cell malignancies.